# A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency

- **DOI:** [10.1093/cei/uxae121](https://doi.org/10.1093/cei/uxae121)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** A valuable national rare-disease cohort that strengthens descriptive evidence, but its treatment recommendations outrun the small uncontrolled response groups.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Fcei%2Fuxae121

## Key claims

1. Antifibrinolytics and attenuated androgens showed comparable efficacy to LTP, at 88.9% and 89.5%, respectively.
   - Support: Supported
   - Type: Primary finding
   - Basis: retrospective clinician-assessed comparison without random allocation or confounder adjustment
   - Location: Abstract; Results, “Comparison of the efficacy of androgens and antifibrinolytics”; Table 4
2. The median age at AAE-C1-INH diagnosis was 65 years with 3.4% of patients diagnosed below 40 years.
   - Support: Well-supported
   - Type: Secondary
   - Basis: direct descriptive frequencies from the full 117-patient cohort
   - Location: Abstract; Results, “Demographic and clinical profile”; Table 1
3. A haematological disorder was identified in 83.8% of AAE-C1-INH patients compared to 3.4% of autoimmune diseases.
   - Support: Well-supported
   - Type: Secondary
   - Basis: direct cohort counts reported consistently in the abstract and Table 3
   - Location: Abstract; Results, “The profile of AAE-associated disorders”; Table 3
4. The predominant haematological disorder in the UK cohort was SZL followed by MGUS.
   - Support: Well-supported
   - Type: Secondary
   - Basis: consistent full-cohort percentages in the abstract and Table 3 despite one denominator typo in the text
   - Location: Conclusion; Table 3
5. Rituximab monotherapy was effective in treating 9/9 splenic marginal zone lymphoma and 1/2 MGUS-associated AAE-C1-INH.
   - Support: Tentative
   - Type: Secondary
   - Basis: small selected treatment groups within an uncontrolled retrospective audit
   - Location: Abstract; Results, “Effect of treatment of AADs on AAE symptoms”; Table 5A

## Strengths

- **Broad national specialist-centre coverage** The survey includes 117 patients from 25 of 34 adult UK Clinical Immunology and Allergy centres, providing substantial national coverage for an exceptionally rare disorder.
  - Dimension: contribution
  - Location: Methods, “Data collection”
- **Systematic European cohort comparison** Tables 3–6 compare disease associations, prophylaxis, rituximab experience, and immunochemical testing across five European cohorts, allowing UK-specific patterns to be distinguished from recurring findings.
  - Dimension: positioning
  - Location: Tables 3–6; Discussion
- **Transparent reporting of study constraints** The Methods and Limitations sections identify retrospective clinician reporting, cross-centre assay variation, small subgroups, and unavailable chronological biomarker data. Missing denominators are also reported in the tables.
  - Dimension: methodological rigour
  - Location: Methods, “Variables”; Table 1; Limitations

## Limitations

- **Treatment inference exceeds observational design** The recommendation to consider B-cell depletion without haematological indications rests on small, selected, uncontrolled treatment groups with clinician-assessed outcomes. These observations are hypothesis-generating rather than comparative evidence of effectiveness.
  - Dimension: methodological rigour
  - Location: Results, Table 5; Conclusion
- **Biomarker independence claim is underpowered** The abstract describes rituximab efficacy as independent of anti-C1INH-autoantibody detection, but the comparison comprises only 3/3 seronegative and 4/4 seropositive patients. The Results section itself acknowledges that the sample was small.
  - Dimension: reporting
  - Location: Abstract; Results, “Anti-CINH-autoantibodies as a marker for AAE response to Rituximab”; Table 5B
- **Incomplete and heterogeneous outcome measurement** Anti-C1INH-autoantibodies were tested in only 27 of 117 patients without an explained selection mechanism, while complement and antibody findings were reduced to binary categories across varying assays and eras.
  - Dimension: methodological rigour
  - Location: Methods, “Variables”; Results, “Immunochemical profile”; Table 6

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The principal descriptive results are coherent across the abstract and tables, but several treatment-response statements require caution because of small or unclear denominators. A denominator notation error in the associated-disorders Results paragraph does not alter the corresponding figures in the abstract or Table 3.
- **Research conduct:** Clean. Ethical handling of the anonymised retrospective audit is declared, conflicts and funding are disclosed, and data availability is stated. No text-grounded research-conduct inconsistency was identified.
- **Reference integrity:** Clean. 13 of 13 checkable references verified
  - 13 references in manuscript
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17